Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Frontline treatment of transplant-ineligible MM: a changing landscape

The majority of multiple myeloma (MM) patients are not transplant eligible – although the definition of transplant eligibility is now changing. Here, Noopur Raje, MD, from Massachusetts General Hospital, Boston, MA, gives her thoughts on the best frontline therapy for this patient group. Dr Raje highlights data from the ALCYONE (NCT02195479), SWOG (NCT01903811) and RVD Lite (NCT01782963) trials, and emphasizes the importance of achieving deep remissions even in elderly patients. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.